A Study of YL202 in Selected Patients With Advanced Solid Tumors
Trial Parameters
Brief Summary
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in the following selected patients with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria: 1. Subjects who are aware of relevant trial information before the start of the trial, and voluntarily sign and date on the informed consent form (ICF). 2. Subjects aged from 18-75 (inclusive) years. 3. Histologically or cytologically confirmed at diagnosis of NSCLC/BC/HNSCC/other locally advanced or metastatic solid tumors including but not limited to colorectal cancer, HER2-positive gastric cancer, cervical cancer, ovarian cancer, etc.. 4. At least one extracranial measurable lesion according to RECIST 1.1. 5. Archived or fresh tumor tissue samples can be provided. 6. With Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1. 7. The function of organs and bone marrow meets the requirements within 7 days before the first dose. 8. Female subjects of childbearing potential must agree to adopt highly effective contraceptive measures from screening throughout the study period and within at least 6 months after the last dose of the investigati